• SMV5: Dr. Michael Triplett, CEO of Myonexus Therapeutics on its sale to Sarepta

  • Jun 3 2021
  • Length: 51 mins
  • Podcast

SMV5: Dr. Michael Triplett, CEO of Myonexus Therapeutics on its sale to Sarepta

Listen for free

View show details

  • Summary

  • This episode of the SmartMoney Ventures Podcast features Dr. Michael Triplett, CEO of Myonexus Therapeutics who, along with co-founder Dr. Louise Rodino-Klapac, successfully completed a 9 figure exit event before securing Series A financing.

    The story illustrates how successful tech transfer and strategic positioning resulted in the establishment of a new Gene Therapy Center of Excellence creating over 100 new jobs while transforming Muscular Dystrophy patient treatments.

    Prior to co-founding Myonexus, Michael held leadership positions at Proctor & Gamble, Battelle Memorial Institute and Ventaira Pharmaceuticals among others.

    In this episode, you will learn:

    1. How to get a 9 figure exit before your Series A financing
    2. How Technology Transfer is transforming the Heartland Region
    3. Why resilience is a big part of entrepreneurial psychology
    4. Sage advice for technical & scientific founders
    5. How a Gene Therapy Center of Excellence was established in Central Ohio

    Dr. Triplett holds both a bachelor’s degree and a Ph.D. in Chemical Engineering from THE Ohio State University graduating Summa Cum Laude.

    Show more Show less
Show more Show less
activate_Holiday_promo_in_buybox_DT_T2

What listeners say about SMV5: Dr. Michael Triplett, CEO of Myonexus Therapeutics on its sale to Sarepta

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available